DDInter98 DDInter899
Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Anisindione {u} (Compound) resembles {v} (Compound) Diltiazem
Anisindione {u} (Compound) resembles {v} (Compound) Oxybenzone
Anisindione {u} (Compound) binds {v} (Gene) GGCX
Anisindione {u} may cause a minor interaction that can limit clinical effects when taken with {v} Acarbose
Anisindione {u} may cause a minor interaction that can limit clinical effects when taken with {v} Olsalazine
Anisindione {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Anisindione {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amoxicillin
Anisindione {u} may lead to a major life threatening interaction when taken with {v} Defibrotide
Anisindione {u} may lead to a major life threatening interaction when taken with {v} Lepirudin
Anisindione {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Flurbiprofen
Anisindione (Compound) resembles Diltiazem (Compound)
Anisindione (Compound) resembles Oxybenzone (Compound)
Anisindione (Compound) binds GGCX (Gene)
Anisindione may cause a minor interaction that can limit clinical effects when taken with Acarbose
Anisindione may cause a minor interaction that can limit clinical effects when taken with Olsalazine
Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Amoxicillin
Anisindione may lead to a major life threatening interaction when taken with Defibrotide
Anisindione may lead to a major life threatening interaction when taken with Lepirudin
Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Anisindione may lead to a major life threatening interaction when taken with Flurbiprofen